NCT02879617 - A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 4, 2017

Primary Completion Date

June 4, 2022

Study Completion Date

June 4, 2022

Conditions

Non-Small Cell Lung Cancer NSCLC

Interventions

DRUG

durvalumab

A human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against programmed cell death ligand 1 (PD-L1)

Trial Locations (2)

UPMC Hillman Cancer Center, Pittsburgh

Simmons Comprehensive Cancer Center - UT Southwestern Medical Center, Dallas